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showed a dominance profile in 84% and 90% of all simulations.CONCLUSIONS:The
early use of Sevelamer in NDD-CKD patients proved more effective and less costly,
generating good value for money from the NHS perspective.
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OBJECTIVES: There are numerous publications on the effects of Ketosteril (a keto-
acid-aminoacid oral preparate) both in predialysis and dialysis patients. No data
exists, however, to the authors’ knowledge regarding its pharmacoeconomic im-
pact on the treatment of predialysis patients. Our aim was to evaluate the cost-
effectiveness of Ketodiet (low/very low protein diet plus Ketosteril) started in stage
3 (GFR 60-30 ml/min) of chronic kidney disease (CKD) versus starting it in stage 4
(GFR 30-15 ml/min) of CKD. A simulation model has been developed to compare the
relative costs and health-benefits of the two alternatives. METHODS: Therapeuti-
cally effectiveness was clarified on published Hungarian Ketosteril studies (n171).
GFR progression was estimated with a mixed (fixed and random effect) regression
analysis of the data for patients treated with and without early Ketosteril for de-
terministic modeling. 1000 hypothetical patient curves were generated using
Bayesian approach to assure the validity of our preliminary hypothesis regarding
the expected time to dialysis. Cost analysis based on 80 recent Hungarian CKD
patients’ multicenter (n9) financial resource utilization data. Quality-adjusted life
year (QALY) values were assigned to the CKD stages to assess the qualitative and
quantitative impact of the two different Ketodiet approaches. A deterministic and
probabilistic model was developed for cost-effectiveness analysis. During lifelong
modeling costs and outcomes were discounted with official Hungarian rate of 5%.
RESULTS: Deterministic modeling showed a cost favour of 6 543,48 € with early
(CKD 3) Ketodiet start. Early initiation proved to be also more effective (avg. differ-
ence: 0,71 QALY). ICER of the deterministic model (-9 216,17 €/QALY) and 76% of
cases in the probabilistic analysis resulted in a dominance with this approach.
CONCLUSIONS: Early initiation of the Ketodiet in stage 3 CKD proved to be more
advantageous in terms of both health care costs and outcomes than starting the
treatment in stage 4 CKD.
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OBJECTIVES: To perform economic evaluation of pazopanib in comparison with
sunitinib, sorafenib and bevacizumab  interferon -2a for patients with meta-
static renal cell carcinoma (mRCC).METHODS: Indirect comparison was performed
to assess the relative efficacy of studied drugs. Pazopanib was compared with
sunitinib and bevacizumab  interferon -2a in the first-line treatment and with
sorafenib in the second-line treatment of patients with mRCC. The probability of
progression-free survival (PFS) was the criteria of clinical efficacy. Costs of drugs
were calculated based on data about the prices of public purchases. Cost-minimi-
zation analysis was performed. One-way sensitivity analysis was made to assess
the impact of prices’ variations (minimal – maximal price range) on the results.
RESULTS: Indirect comparison showed no statistically significant differences in
PFS between compared drugs. The rate of severe adverse events was low for all
drugs and should not affect the costs. The cost-minimization difference for pazo-
panib was —371.44 thousands rub (—11.09 thousands $) in comparison with
sorafenib, —660. 12 thousands rub (—19.70 thousands $) in comparison with
sunitinib and —1.98 millions rub (—59.20 thousands $) in comparison with bevaci-
zumab  interferon -2a per patient. The sensitivity analysis showed that varia-
tions in prices do not affect the results and pazopanib remains a cost-saving
option. CONCLUSIONS: Pazopanib is more efficient alternative in comparison with
sunitinib, sorafenib and bevacizumab  interferon -2a for patients with mRCC.
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OBJECTIVES: Neither national nor international clinical guidelines do consistently
recommend treating non-diabetic proteinuric patients with advanced renal dis-
ease with an angiotensin-converting enzyme (ACE) inhibitor. The aim of our study
was to determine the cost-effectiveness of ACE inhibitor therapy in non-diabetic
proteinuric patients with advanced renal disease in the Netherlands. METHODS:
Two strategies were compared: treating patients with advanced renal disease with
an ACE inhibitor and no ACE inhibitor treatment. A lifetime Markov decision model
was developed using published data on costs and health outcomes and simulating
the progression of renal disease. A health care perspective was adopted. RESULTS:
In the base-case analysis, ACE inhibitor treatment is associated with lower costs
and higher benefit and therefore dominates the no-treatment strategy. A probabi-
listic sensitivity analysis shows that the probability of savings is 83%.
CONCLUSIONS: ACE inhibitor treatment for non-diabetic patients with advanced
renal disease in the Netherlands is highly cost-effective. Savings would be even
larger if prevention of cardiovascular events were considered.
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OBJECTIVES: Treatment persistence to pharmacological OAB treatment is known
to be low and may vary by type of antimuscarinic used. The aim of this study was
to estimate treatment persistence associated with fesoterodine, solifenacin or tolt-
erodine in routine clinical practice in Spain. METHODS: A retrospective study was
conducted using Primary Care electronic medical records from three towns in
Spain. Records from patients who newly initiated OAB treatment between January
2008 and December 2010, with at least 52 weeks of follow-up, were retained. Male
and female patients, over 18, with a diagnosis of OAB [ICD-9-CM 596.51], and a new
prescription of fesoterodine, tolterodine or solifenacin were included in this anal-
ysis. Pattern of treatment persistence was assessed using a Cox-proportional haz-
ard regression model and binary logistic regression adjusting for study location,
age, sex, medication possession ratio, co-morbidity burden and time since
diagnosis. RESULTS:A total of 1971 records (58.3% women, mean age 70.1 [SD:10.6])
were analyzed; 302 treated with fesoterodine, 952 with solifenacin and 717 with
tolterodine. Unadjusted mean treatment duration was 31.5 (17.6) weeks for fesot-
erodine, 29.9 (21.4) for solifenacin, and 29.0 (21.6) for tolterodine, p0.217. Cumu-
lative adjusted likelihood of discontinuation at 52 weeks was on average 22%
higher for solifenacin [Hazard Ratio 1.22 (1.03;1.44); p0.020] and 25% higher for
tolterodine [HR 1.25 (1.05;1.49); p0.014] than fesoterodine. At week 52, 37.1% of
fesoterodine-treated patients remained on initial therapy versus 33.1% solifena-
cin-treated [adjusted OR0.77 (0.58;1.03), p0.078] and 32.1% tolterodine-treated
[adjusted OR0.75 (0.55;1.03),p0.075] patients. CONCLUSIONS: Cumulative like-
lihood of discontinuating new antimuscarinic treatment for OAB over a 52-week
was significantly higher for solifenacin or tolterodine compared to fesoterodine in
Spanish clinical practice, yielding to a trend toward higher persistent rates at 52
weeks for fesoterodine.
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OBJECTIVES: Lower urinary tract symptoms (LUTS) due to Benign Prostatic Hyper-
plasia (BPH) are very common in men over age 50. BPH treatments allow the im-
provement of LUTS, the reduction of risk of acute urinary retention (AUR) and
BPH-related surgery. However, some LUTS treatments have adverse events that
can lead to poor adherence to BPH medications. It is therefore critical to monitor
adherence and facilitate communication between patients and clinicians in clini-
cal practice. The objective was to develop a scale to evaluate patient adherence and
help clinicians in the management of BPH patients.METHODS: Patient exploratory
interviews were conducted by a health psychologist among 15 men with BPH,
following a non-directive technique so that concepts were mentioned spontane-
ously by patients. The numerous concepts identified were discussed with experts
and relevant concepts for adherence were organised into a conceptual model.
RESULTS: The conceptual model included various factors linked to adherence:
patient characteristics, disease and therapy-related factors, patients’ experiences,
knowledge, beliefs, concerns and motivations, expectations, acceptance, inten-
tions, patients’ behaviours and attitudes and environmental factors. Items were
then generated for each relevant concept using patients’ own words. The scale
contains 53 items and is being tested for relevance and comprehension.
CONCLUSIONS:This scale aims to encourage patients to ask questions and express
any doubt or concerns they may have about treatment, and help clinicians identify
patients facing adherence issues. It will enable the clinicians to monitor treatment
acceptance and adherence to prescribed treatment. A future pilot study with 10
clinicians and 30 BPH patients is planned in real conditions of use to assess if the
scale will be well accepted by both clinicians and patients in clinical practice. A
validation study will then be undertaken to validate psychometric properties and
scoring of the scale, and to evaluate the ability of the score to predict adherence and
persistence.
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OBJECTIVES: Due to its longer half-life, darbepoetin alfa (DA) is administered at
extended dosing intervals compared to epoetin alfa (EPO). The aim of this study
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was to collect, in routine clinical practice, data about consequences of switching
from intravenous (IV) EPO to IV DA in patients (pts) with chronic kidney disease
(CKD) receiving dialysis ( 12 months). METHODS: This French monocentre obser-
vational study included adults with CKD receiving dialysis switched from EPO to
DA in July 2010. Data related to EPO and DA dosing and dose frequency, Hb levels,
and iron statuses were collected retrospectively over 36 weeks before the conver-
sion and 36 weeks after the conversion. The primary endpoint estimated the dose
conversion ratio (DCR) between mean EPO doses (UI) and DA (g) during 4 weeks
pre-conversion and 21-24 weeks post-conversion. The mean DCR was determined
with a regression-based method using ordinary least squares (LSQ). RESULTS: A
total of 93 pts were enrolled in this study, (61.3 % female, mean age 70.3 years
(mean time on dialysis 5.2 years). The primary etiologies of CKD were mainly dia-
betes (37.6 %) and hypertension (12.9 %). The arithmetic mean ( SD) EPO dose/
injection at inclusion was 4193  3417 UI with the following injection frequency:
x3/week (44.1 %), x2/week (32.3 %), x1/week (21.5 %) or other (2.1 %). The mean (
SD) DCR on the evaluable population (83 patients, 10 excluded due to missing data)
was 271.3  30.4 (95% CI 264.7, 277.9). The mean ( SD) Hb values were equivalent
over the pre- and post-conversion periods 11.2  0.9 and 11.1  1.0 g/dL, respec-
tively. Iron status was also similar. CONCLUSIONS: In routine clinical practice, the
mean DCR observed in our French dialysis centre, was higher than the factor 200UI:
1g recommended in the DA Summary of Product Characteristics and applied at
switch.
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OBJECTIVES: Kidney transplantation is perceived to be highly cost effective; the
cost of post-transplant management is modest compared to dialysis and quality of
life is significantly improved. While graft survival rates have improved substan-
tially in recent years, on average, graft failure rates are currently 2.9% per annum
across the UK. The objective of this study was to quantify the minimum graft
survival time required for transplantation to remain cost saving compared to
dialysis. METHODS: We utilized a simple decision analytic model with published
input costs for dialysis; immunosuppression and other post-transplant manage-
ment costs were obtained from the PORTRAIT Study (a retrospective observational
study of renal transplant patients) and UK NHS reference costs used for transplan-
tation. We compared the costs of continued dialysis with transplantation and eval-
uated the number of years of functioning graft required for transplantation to
remain cost saving. Future costs were discounted at 3.5%. RESULTS: Over a 10 year
time horizon the total per-patient costs associated with remaining on dialysis was
£394,379; over the same period the total per-patient cost for a functioning graft
were £118,049 representing a saving to the NHS of £276,330 per-patient. Patients
with a 3-year functioning graft prior to returning to dialysis cost an additional
£5,723 compared to remaining on dialysis while 4-year graft survival was cost
saving. CONCLUSIONS: For kidney transplantation to be cost saving recipients
must maintain at least 3 years of functioning graft. In the UK between 3% to 13% of
adult kidney transplants from deceased donors and 2% to 8% from living donors fail
within one year necessitating a return to dialysis. Consequently, a substantial
number of transplant recipients in the UK incur additional and substantial expen-
diture due to poor graft survival rates and, therefore, management strategies to
maximize graft survival should be prioritized in these patients.
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Chronic Kidney Disease (CKD) is the second most frequent complication in 7 mil-
lion diabetes patients in Germany. However, available data on burden of disease is
intransparent. OBJECTIVES: To obtain a comprehensive picture on the conse-
quences of CKD in diabetes patients in Germany from the epidemiological, clinical
and health economics perspective based on available scientific literature.
METHODS: A semi-structured systematic literature review in MEDLINE, CO-
CHRANE, EMBASE and national associations over the last 10 years (2001-2011) and
relevant congress abstracts over the last 2 years. Fields of interest (reviewed sepa-
rately) were epidemiology, health economics, burden of disease and treatment
guidelines with reference to CKD and diabetes. As a conclusion, we conducted a
data gap analysis. RESULTS: Twenty-one epidemiological, 12 burden of disease, 9
health economic full-text articles and 5 treatment guidelines were identified. Prev-
alence of CKD in diabetes patients was 39% but only 0.5% reached dialysis. Acces-
sion rates within all CKD stages were missing. Yearly mortality rates within diabe-
tes patients in dialysis were around 20%. An albumin guideline adherence (albumin
level below 40g/L) could save 23,578 life years. SF-36 was most common generic
HRQoL and KDQoL as disease specific. No data on QoL in pre-dialysis was available.
Highest impairment was physical and emotional functioning. Poor sleep quality
(63%) was significantly associated with higher risk of death (RR1.16, p0.002).
Health care costs were significantly associated with progression of CKD stages.
Direct costs of dialysis were 54,777 €. 60% of dialysis patients lived below the pov-
erty level. CONCLUSIONS: Higher evidence on epidemiological data and disease pro-
gression is desirable. Data within patients in CKD 1-4 was limited or not available. Produc-
tivity lossmighthaveasignificant impactontheburdenofdiseasebutnodatawasfound.
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OBJECTIVES: The number of patients suffering from chronic kidney disease (CKD)
is about 10% of the total world population and 50% of patients with hypertension
and diabetes. About 3400 patients with CKD in Ukraine are treated by hemodialysis.
All these patients need treatment of anemia that associates with CKD by erythro-
poietins (EPs). In Ukraine as well as alfa- and beta-erythropoietins a fundamentally
new product – continuous erythropoietin receptor activator (CERA) are recom-
mended. Its main feature - administration twice a month in treated dose and once
a month in maintenance dose, while others EPs are administrated 2-3 times a
week. The purpose of research is comparative pharmacoeconomic evaluation of
maintenance treatment of anemia in patients with CKD on hemodialysis stage by
different drugs of erythropoietin. METHODS: Decision tree and cost-effectiveness
analysis were used. The costs for EP drugs were determined according to the price
list Pharmacy (2011). The data about equivalent doses of different EPs and their
effectiveness are taken from the results of randomized clinical trials phase III
MAXIMA, PROTOS and RUBRA. RESULTS: Showed that prolonged use of CERA,
which is administrated once a month, effectively maintained stable hemoglobin
level previously is achieved by the administration of shorter-acting EPs (3 times a
week). With appropriate regimen of administration in equivalent doses (according
to the instruction of CERA) the average costs of CERA treatment per patient on
hemodialysis are $173/week (i/v route of administration) and $130/week (s/c route
of administration). The average costs for using the shorter-acting EP drugs are
$267-194/week and $133-182/week respectively. CONCLUSIONS: The use of CERA
in patients with CKD on hemodialysis at the compensative stage instead of shorter-
acting EPs saves about 5-35% of cost for anemia pharmacotherapy. The effective-
ness and safety of therapy do not change.
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OBJECTIVES: Previous research has described treatment failure as discontinuation
of the first anticholinergic or switching in persons with continuous anticholinergic
use. Such research does not account for persons who may restart anticholinergic
use following a period of discontinuation. The objective of this study was to eval-
uate the dynamics of treatment failure in patients with OAB following discontin-
uation of the first anticholinergic.METHODS: Patients in a US commercial database
between January 2005 and June 2010 with  1 filled prescription for an anticholin-
ergic for OAB were included. Treatment failure was defined as patients who dis-
continued therapy (treatment gap of45 days) or switched medications. RESULTS:
There were 182,586 patients who met all inclusion criteria. Treatment failure was
present in a total of 83.4% patients, with 78.3% of patients discontinuing first antich-
olinergic therapy and 5.1% of continued users switching. A total of 30.4% of persons
who discontinued treatment rechallenged after the 45 day treatment gap, with 66.7%
resuming treatment with their original agent. Overall, 54.5% of patients discontinued
anticholinergic treatment permanently within the one year study period. A total of
14.1% of patients switched at least once throughout the study, and patients received
an average of 1.2 (SD: 0.4) unique anticholinergic agents. Of those who initially
switched to a second anticholinergic, 69.6% of patients failed treatment for a second
time either by discontinuing treatment (48.8%) or switching to a third agent (20.8%). A
separate analysis requiring  2 fills found that 85% of patients who switched also
discontinued within the one year study frame. Persons on sustained release anticho-
linergics were less likely to experience treatment failure than those on immediate
release anticholinergics (odds ratio: 0.78 [0.76-0.80], P0.0001).CONCLUSIONS: Treat-
ment failure was high in patients taking anticholinergics for OAB even after taking
restarts into account. Most patients who switched from their first anticholinergic ther-
apy experienced a second treatment failure.
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KAPLAN-MEIER SURVIVAL CURVES: A POTENTIAL SOURCE OF DATA FOR
SYSTEMATIC REVIEWS
Gupta J, Bhutani MK, Kumar R, Kaur M, Jindal R, Siddiqui MK
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OBJECTIVES: Kaplan-Meier (KM) curves are commonly used to report time-to-
event outcomes like overall survival (OS) and progression-free survival. For studies
not explicitly reporting hazard ratio (HR) and confidence intervals (CI), KM curves
can be utilised to estimate these summary statistics for conducting a meta-analy-
sis. Here, we validate the method proposed by Parmar and colleagues for estimat-
ing HR (95%CI) by reading the KM curves. METHODS: Ten randomised controlled
trials reporting HR (95%CI) and the associated KM curve for OS were randomly
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